These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 18329630)

  • 1. Quercetin pretreatment increases the bioavailability of pioglitazone in rats: involvement of CYP3A inhibition.
    Umathe SN; Dixit PV; Kumar V; Bansod KU; Wanjari MM
    Biochem Pharmacol; 2008 Apr; 75(8):1670-6. PubMed ID: 18329630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of quercetin on the pharmacokinetics of Etoposide after oral or intravenous administration of etoposide in rats.
    Li X; Choi JS
    Anticancer Res; 2009 Apr; 29(4):1411-5. PubMed ID: 19414395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Cinnamomum cassia on the Pharmacokinetics and Pharmacodynamics of Pioglitazone.
    Mamindla S; Koganti VSRGP; Ravouru N; Koganti B
    Curr Clin Pharmacol; 2017; 12(1):41-49. PubMed ID: 28176623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Phyllanthus amarus on the pharmacokinetics of midazolam and cytochrome P450 activities in rats.
    Taesotikul T; Nakajima M; Tassaneeyakul W; Yokoi T
    Xenobiotica; 2012 Jul; 42(7):641-8. PubMed ID: 22339466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory effect of docosahexaenoic acid (DHA) on the intestinal metabolism of midazolam: in vitro and in vivo studies in rats.
    Hirunpanich V; Murakoso K; Sato H
    Int J Pharm; 2008 Mar; 351(1-2):133-43. PubMed ID: 18082981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin.
    Choi JS; Piao YJ; Kang KW
    Arch Pharm Res; 2011 Apr; 34(4):607-13. PubMed ID: 21544726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
    Yamano K; Yamamoto K; Katashima M; Kotaki H; Takedomi S; Matsuo H; Ohtani H; Sawada Y; Iga T
    Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone.
    Yumoto R; Murakami T; Sanemasa M; Nasu R; Nagai J; Takano M
    Drug Metab Dispos; 2001 Feb; 29(2):145-51. PubMed ID: 11159804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of oral bioavailability of rivastigmine with quercetin nanoparticles by inhibiting CYP3A4 and esterases.
    Palle S; Neerati P
    Pharmacol Rep; 2017 Apr; 69(2):365-370. PubMed ID: 28189992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity.
    Wang Z; Gorski JC; Hamman MA; Huang SM; Lesko LJ; Hall SD
    Clin Pharmacol Ther; 2001 Oct; 70(4):317-26. PubMed ID: 11673747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
    Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
    Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of pioglitazone on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rats.
    Choi JS; Burm JP
    Arch Pharm Res; 2008 Sep; 31(9):1200-4. PubMed ID: 18806964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of pioglitazone in lean and obese cats.
    Clark MH; Hoenig M; Ferguson DC; Dirikolu L
    J Vet Pharmacol Ther; 2012 Oct; 35(5):428-36. PubMed ID: 22612529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats.
    Shin SC; Choi JS; Li X
    Int J Pharm; 2006 Apr; 313(1-2):144-9. PubMed ID: 16516418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin.
    Choi JS; Jo BW; Kim YC
    Eur J Pharm Biopharm; 2004 Mar; 57(2):313-8. PubMed ID: 15018990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats.
    Muzeeb S; Venkatesh P; Mullangi R; Srinivas NR
    Xenobiotica; 2006 Sep; 36(9):838-56. PubMed ID: 16971347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of rifampicin on the pharmacokinetics of pioglitazone.
    Jaakkola T; Backman JT; Neuvonen M; Laitila J; Neuvonen PJ
    Br J Clin Pharmacol; 2006 Jan; 61(1):70-8. PubMed ID: 16390353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of CYP3A inhibition on vesnarinone metabolism in humans.
    Wandel C; Lang CC; Cowart DC; Girard AF; Bramer S; Flockhart DA; Wood AJ
    Clin Pharmacol Ther; 1998 May; 63(5):506-11. PubMed ID: 9630823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone.
    Tornio A; Niemi M; Neuvonen PJ; Backman JT
    Drug Metab Dispos; 2008 Jan; 36(1):73-80. PubMed ID: 17913794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of curcumin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen, in rats: possible role of CYP3A4 and P-glycoprotein inhibition by curcumin.
    Cho YA; Lee W; Choi JS
    Pharmazie; 2012 Feb; 67(2):124-30. PubMed ID: 22512082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.